Acquired Company

XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation, completed the acquisition of Mural Oncology plc on December 5, 2025.

Mural Oncology plc is an innovative biotechnology firm at the forefront of developing targeted therapies aimed at addressing unmet medical needs in the treatment of solid tumors. Leveraging proprietary platforms, the company harnesses the immune system to enhance patient outcomes through its robust pipeline of drug candidates. Mural's commitment to clinical excellence, coupled with strategic partnerships, positions it as a pivotal player within the oncology sector, striving to deliver breakthrough therapies. As it advances its promising clinical programs, Mural remains steadfast in its mission to improve the lives of cancer patients through precision medicine. Show more

10 EARLSFORT TERRACE, DUBLIN, IRELAND, D02 T380, Dublin, D02 T380, USA

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

35.38M

52 Wk Range

$0.95 - $4.35

Previous Close

$2.04

Open

$2.04

Volume

N/A

Day Range

$2.04 - $2.04

Enterprise Value

-19.94M

Cash

58.87M

Avg Qtr Burn

-18.48M

Insider Ownership

13.41%

Institutional Own.

46.57%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nemvaleukin alfa (ALKS 4230) (IL-2) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nemvaleukin alfa +/- pembrolizumab Details Mucosal melanoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nemvaleukin alfa + pembrolizumab Details Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.